CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Explore linked clinical trials.39 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer | HER2-Negative Advanced Breast Cancer | Not yet recruiting | Phase 3 | 2026-09-04 | NCT07805135 | |
| A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza. | Infections, RNA Virus Infections, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Not yet recruiting | Phase 2 | 2026-09-01 | NCT07798193 | |
| A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 1 | 2026-08-12 | NCT06688435 | |
| Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants. | Healthy Participants | Recruiting | Phase 1 | 2026-08-11 | NCT07756996 | |
| A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function | Healthy Participants; Participants With Moderate Renal Impairment | Recruiting | Phase 1 | 2026-07-10 | NCT07694869 | |
| A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function | Healthy Participants; Participants With Mild Hepatic Impairment; Participants With Moderate Hepatic Impairment | Recruiting | Phase 1 | 2026-07-10 | NCT07694843 | |
| SYH2095 for Advanced Malignant Tumors: Phase I Study | Advanced Malignant Tumors | Not yet recruiting | Not stated | 2026-07-09 | NCT07692776 | |
| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma | Neoplasms by Histologic Type, epithelioid hemangioendothelioma, hemangioendothelioma, hemangioma, neoplasm, vascular cancer | Not yet recruiting | Phase 2 | 2026-07-06 | NCT07684287 | |
| A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly | Diagnosed With Acromegaly, Currently in the Active Stage of the Disease | Not yet recruiting | Phase 3 | 2026-06-03 | NCT07623824 | |
| Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | Gastroenteropancreatic Neuroendocrine Tumors | Recruiting | Phase 2 / Phase 3 | 2026-04-24 | NCT07165886 | |
| A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 1 | 2026-04-16 | NCT07532655 | |
| A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-02-18 | NCT07418736 | |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 | Healthy Participants | Recruiting | Phase 1 | 2026-02-17 | NCT07412353 | |
| Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | Advanced Hepatocellular Carcinoma (HCC) | Not yet recruiting | Phase 1 / Phase 2 | 2025-12-15 | NCT07282509 | |
| A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-11-28 | NCT07241936 | |
| A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) | methylmalonic acidemia | Not yet recruiting | Phase 3 | 2025-09-09 | NCT07163364 | |
| Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Recruiting | Phase 2 | 2025-09-08 | NCT06947291 | |
| Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases | Colorectal Liver Metastases; First-line Treatment | Recruiting | Phase 1 | 2025-08-12 | NCT07117435 | |
| HB1801 Combined Treatment of HER2-positive Breast Cancer | HER2-positive Breast Cancer | Not yet recruiting | Phase 2 | 2025-08-12 | NCT07116824 | |
| A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | Advanced Breast Cancer | Not yet recruiting | Phase 2 | 2025-07-24 | NCT07083505 | |
| Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Not yet recruiting | Phase 2 | 2025-06-03 | NCT06562894 | |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2025-05-31 | NCT04668690 | |
| Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-05-04 | NCT06957379 | |
| A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer | Advanced Breast Cancer | Not yet recruiting | Phase 1 | 2025-04-23 | NCT06941142 | |
| Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 3 | 2025-04-16 | NCT06929325 |